Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Rollover Study of Oral Azacitidine (CC-486) for Long-Term Safety
2016-000069-22Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in Nonhematologic neoplasms, hematopoietic malignancies and cancer, sponsored by Celgene Corporation. Primary endpoint: Long-term safety of CC-486. Started Jan 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
Nonhematologic neoplasmshematopoietic malignanciescancer
Beyond the preview
Go deeper on 2016-000069-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000069-22.